A review and assessment of potential sources of ethnic differences in drug responsiveness

Journal of Clinical Pharmacology

Volumn 43, Issue 9, 2003, Pages 943-967

  Bjornsson, Thorir D ^a   Wagner, John A ^b   Donahue, Stephen R ^c   Harper, Dawn ^a   Karim, Aziz ^d   Khouri, Marlene S ^c   Murphy, William R ^a   Roman, Kristin ^b   Schneck, Dennis ^e   Sonnichsen, Daryl S ^c   Stalker, Dennis J ^d   Wise, Stephen D ^f   Dombey, Stuart ^g   Loew, Caroline ^g  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Pharmacia   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Eli Lilly Singapore Pte Ltd   (Singapore)

^g Pharmaceutical Research and Manufacturers of America   (United States)

Author keywords

Drug development and registration; Drug responsiveness; Ethnic differences; ICH E5 guidelines

Indexed keywords

ACYLTRANSFERASE; AGENTS ACTING ON THE GENITAL SYSTEM; AGENTS AFFECTING METABOLISM; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CELECOXIB; CENTRAL NERVOUS SYSTEM AGENTS; CODEINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; GASTROINTESTINAL AGENT; HALOPERIDOL; IBUPROFEN; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MORPHINE DERIVATIVE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; PSYCHOTROPIC AGENT; RANITIDINE; RESPIRATORY TRACT AGENT; UNINDEXED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG REGISTRATION; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNOPHARMACOLOGY; HUMAN; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; REGISTRATION; REVIEW; SIDE EFFECT;

EID: 0043014561     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003256065     Document Type: Review

References (225)

1. Wood AJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin Pharmacokin 1991;20:350-373.
2. Levy RA: Ethnic and racial differences in response to medicines: preserving individualized therapy in managed pharmaceutical programmes. Pharm Med 1993;7:139-165.
3. Kalow W, Bertilsson L: Interethnic factors affecting drug response. Adv Drug Res 1994;25:1-59.
4. Renwick AG: Inter-ethnic differences in xenobiotic metabolism. Environment Toxicol Pharmacol 1996;2:165-170.
5. Xie H-G, Kim RB, Wood AJJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-850.
6. Kalow W: Interethnic differences in drug response, in: Kalow W, Myer UA, Tyndale R (eds.), Pharmacogenomics. New York: Marcel Dekker, 2001;109-134.
7. Harvey C, McAuslane N, Lumley C, Walker S: Current status of CMR survey on inter-ethnic differences in clinical responsiveness, in: Walker SR, Lumley C, McAuslane N (eds.), The Relevance of ethnic Factors in the Clinical Evaluation of Medicines. Dordrecht, the Netherlands: Kluwer Academic, 1994;187-197.
8. Labbe E: A comparison of the clinical evaluation of medicines in Japanese and Caucasian populations, in: Walker SR, Lumley C, McAuslane N (eds.), The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Dordrecht, the Netherlands: Kluwer Academic, 1994;179-186.
9. Naito C: Ethnic effects on pharmacokinetic parameters, in: Walker SR, Lumley C, McAuslane N (eds.), The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Dordrecht, the Netherlands: Kluwer Academic, 1994;161-177.
10. International Conference on Harmonization: E5 ethnic factors in the acceptability of foreign clinical data. Federal Register 1998;63(111). Available: http://www.fda.gov/cder/guidance/2293fnl.pdf
11. Zhou HH, Adedoyin A, Wilkinson GR: Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990;48:10-17.
12. Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA: Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996;42:339-346.
13. Goldstein JA, de Marais SMF: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-299.
14. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, et al: P-450 superfamily: update on the new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996;6:1-42.
15. Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
16. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, et al: The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349.
17. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
18. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P4502C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-458.
19. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, et al: CYP2C Ile 359 and Leu 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000;10:95-104.
20. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, et al: Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br I Clin Pharmacol 1999;48:409-415.
21. Steward DL, Haining RL, Henne KR, Davis G, Rushmore TH, et al: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367.
22. *3 allele. Pharmacogenetics 1999;9:71-80.
23. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
24. Kimura M, Ieiri I, Mamiya K, Urae F, Higuchi S: Genetic polymorphisms of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998;20:243-247.
25. Horai Y, Nakano M, Ishizaki T, et al: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects Japanese versus Mainland Chinese. Clin Pharmacol Ther 1989,46:198-207.
26. Bertilsson L, Lou YQ, Du YL, et al: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
27. Sohn DR, Kusaka M, Ishazaki T, et al: Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-169.
28. Idle JR, Corchero J, Gonzalez FJ: Medical implications of HGP's sequence of chromosome 22. Lancet 2000;355:319.
29. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-296.
30. Gaedigk A: Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 2000;38:61-68.
31. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF: Evidence for a disassociation in the control of sparteine, debrisoquin, and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
32. Sachse C, Brockmoller J. Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
33. Wennerholm A, Johansson I, Masssele AY, Jande M, Alm C, et al: Decreased capacity for debrisoquin metabolism among Black Tanzaniaras: analysis of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999;9:707-714.
34. Masimirembwa CM, Hasler JA: Genetic polymorphism of drug metabolizing enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain ResBull 1997;44:561-571.
35. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, et al: Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996;58:264-268.
36. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, et al: Analysis of the CYP2D6 gene in relation to dextromethorphan Odemethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:570-575.
37. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, et al: Debrisoquin and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6: 441-447.
38. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F, et al: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquin hydroxylation. Mol Pharmacol 1994; 46:452-459.
39. McLellan RA, Oscarson M, Seidegard L, Evans DA: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:87-91.
40. Dahl M-L, Johansson I, Porsmyr-Palmertz M, Ingelman-Sundberg M: Analysis of the CYP2D6 gene in relation to debrisoquin and debrisoquin hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-17.
41. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
42. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580.
43. Guengerich FP: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
44. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
45. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, et al: Population distribution and effects on drug metabolism of a genetic variants in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-294.
46. Kuehl P, Zhang J, Lin Y, Lamba J, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001;27:383-391.
47. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, et al: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 enzymes. Biochem Pharmacol 1992;43:225-235.
48. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al: The major pathway of imipramine is catalysed by cytochromes P-450 1A2 and 3A4 in human liver. Mol Pharmacol 1993;43:827-832.
49. Bertilsson L, Carrillo JA, Dahl ML, Lerena LA, Alm C, Bondesson U, et al: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-473.
50. Rost KL, Brosicke H, Heinemeyer G, Roots I, et al: Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994;20(5):1204-1212.
51. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, et al: Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-127.
52. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, et al: Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP 1A2 gene. Cancer Epidemiol Biomark Prev 1994;3:413-421.
53. Welfare MR, Aitkin M, Bassendine MF, Daly AK: Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 1999;9:367-375.
54. Relling MV, Lin JS, Ayers GD, Evans WE: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-658.
55. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV: Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alphatocopherol. Pharmacogenetics 1997;7:11-19.
56. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, et al: Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 1997;96:599-605.
57. Raunio H, Rautio A, Gullstein H, Pelkonen O: Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001; 52:357-363.
58. Kitagawa K, Kunugita N, Katoh T, Yang M, Kawamoto T: The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun 1999;262:146-151.
59. Nakajima M, Yamagishi S, Yamamoto H, et al: Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 2000;67:57-69.
60. Weber WW, Hein DW: N-acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79.
61. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP, et al: Role of polymorphic and monomorphic human arylamine Nacetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993;45(6):1277-1282.
62. Lundy PKM, Frislid K, Haustein V: Disease and acetylation polymorphism. Clin Pharmacokinet 1977;2:182-197.
63. Perry HM Jr, Tan EM, Carmody S, et al: Relationship of acetyltransferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970;76:114-125.
64. Woosley RL, Drayer DE, Reidenberg MM, et al: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978;298:1157-1159.
65. Grant DM, Huges NC, Janezic SA, Goodfellow GH, Chen HJ, et al: Human acetyltransferase polymorphisms. Mutation Res 1997;376: 61-70.
66. Straka RJ, Hansen SR, Benson SR, Walker PF: Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol 1996;36:740-747.
67. Dhaini HR, Levy GN: Arylamine N-acetyltransferase 1 (NAT1) genotype in a Lebanese population. Pharmacogenetics 2000;10:79-83.
68. Zhou HH, Sheller JR, Nu H, Wood M, Wood AJ: Ethnic differences in response to morphine. Clin Pharmacol Ther 1993;54:507-513.
69. Tornatore KM, Reed KA, Venuto RC: Racial differences in pharmacokinetics of methylprednisolone in Black and White renal transplant recipients. Pharmacotherapy 1993;13(5):481-486.
70. Tornatore KM, Viocevich DM, Reed K, Singh JP, Venuto RC: Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in Black and White renal transplant recipients. Transplantation 1995;59(5):729-736.
71. Magee MH, Blum RA, Lates CD, Jusko WJ: Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race abstract]. Clin Pharmacol Ther 2001;69(2):58.
72. Stephenson DW, Small RE, Wood JH, Willis HE, Johnson SM, Karnes HT, et al: Effect of ranitidine and cimetidine on ibuprofen pharmacokinetics, Clin Pharm 1988;7:317-321.
73. Small RE, Wood JH: Influence of racial differences on effects of ranitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm 1989;8:471-472.
74. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib, a selective cyclo-oxygenase-2 inhibitor [review article]. Clin Pharmacokinet 2000;38(3):225-242.
75. Davies NM, Gudde TW, de Leeuw MA: Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis [review article]. Expert Opin Pharmacother 2001;2(1):139-152.
76. Karim A, Bradford DD, Wallemark C, Brugger A, Laurent A, McMahon FG: Comparative pharmacokinetics of celecoxib in Caucasians and African Americans assessed by intense sampling pharmacokinetic analysis [abstract]. AAPS PharmSci 2001; 3(3).
77. Critchley JAJH, Nimmo GR, Gregson CA, Woolhouse NM, Prescot LF: Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Phormacol 1986;22:649-657.
78. Zhou HH, Sheller JR, Wood M, Wood AJJ: Caucasians are more sensitive than Chinese to the cardiovascular and respiratory effects of morphine but less to the gastrointestinal side effects [abstract]. Clin Res 1990;38(4):968.
79. Houghton IT, Aun CST, Wong YC, Chan K, Lau JTF, Oh TE: The respiratory depressant effects of morphine: a comparative study in three ethnic groups. Anaesthesia 1994;49:197-201.
80. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J: Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989;28:629-637.
81. Yue QY, Svensson JO, Sjoqvist F, Sawe J: A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31(6):643-647.
82. Yue QY, Stevenson JO, Sawe J, Bertilsson L: Codeine metabolism in 3 Oriental populations: a pilot study in Chinese, Japanese and Koreans. Pharmacogenetics 1995;5(3):173-177.
83. Caraco Y, Sheller J, Wood AJJ: Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exper Ther 1999;290(1):413-422
84. Chan K, Tse J, Jennings F, Orme MLE: Disposition of pethidine in man under acidic urinary pH. 3: a comparison of pharmacokinetics among Caucasian, Chinese and Indian subjects. Methods Find Exp Clin Pharmacol 1987;9(4):243-250.
85. Chan K, Tse J, Jennings F, Orme MLE: Disposition of pethidine in man under acidic urinary pH. 4: kinetics after oral dose in Caucasian, Chinese and Indian subjects. Methods Find Exp Clin Pharmacol 1990;12(1):61-67.
86. Houghton IT, Chan K, Wong YC, Aun CST, Lau OW, Lowe DM: Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Find Exp Clin Pharmacol 1992;14(6):451-458.
87. Houghton IT, Chan K, Wong YC, Leuong DH, Aun CS: Biotransformation of pethidine: a comparative study of 24 h urine in three ethnic groups. Eur J Drug Metab Pharmacokinet 1993; 18(3):285-288.
88. Lee A, Gin T, Oh TE: Opioid requirements and responses in Asians. Anaesth Intensive Care 1997;25(6):665-670.
89. Kin KM: Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001;62:13-19.
90. Poolsup N, Li Wan Po A, Knight TL: Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000;25:197-220.
91. Flaskerud JH: Ethnicity, culture and neuropsychiatry. Issues Mental Health Nurs 2000;21:5-29.
92. Ramirez LF: Ethnicity and psychopharmacology in Latin America. Mt. Sinai J Med 1996;63(5-6):330-331.
93. Lawson WB: The art and science of the psychopharmacotherapy of African Americans. Mt. Sinai J Med 1996;63 (5-6):301-305.
94. Risby ED: Ethnic considerations in the pharmacotherapy of mood disorders. Psychopharmacol Bull (US) 1996;32:231-234.
95. Pi EH, Wang AL, Gray GE: Asian/non-Asian transcultural tricyclic antidepressant pharmacology. Prog Neuropsychopharmacol Biol Psychiatry 1993;5:691-702.
96. Shelley RK: Are there ethnic differences in lithium pharmacokinetics and side-effects? Int Clin Psychopharmacol 1987;2:337-342.
97. Lee CF, Yang YY, Hu OY: Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. Aust N Z J Psychiatry 1998;32:133-136.
98. Rudorfer MV, Lane EA, Chang WH, Zhang MD, Potter WZ: Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984;4:433-440.
99. Rudorfer MV, Lane EA, Chang WH, Zhang M, Potter WZ: Crosscultural desipramine pharmacokinetics. Clin Pharmacol Ther 1983;33:243.
100. El Yazigi A, Chaleby K: Study of interethnic differences in the steady state kinetics of imipramine and dozepin. Pharm Res 1987;4:S87.
101. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, et al: Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4′ hydroxylation phenotypes. J Pharmacol Exper Ther 1994;271:860-867.
102. Mahy GE: The effects of clomipramine on depression in Barbadian patients. West Indian Med J 1978;27(2):75-80.
103. Allen JJ, Rack PH, Vaddadi KS: Differences in the effects of clomipramine on English and Asian volunteers: preliminary report on a pilot study. Post Grad Med J 1997;53(Suppl. 4):79-86.
104. Fukuda T, Nishida YY, Zhou Q, Yamamoto I, Kondo S, Azuma J: The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000;56:175-180.
105. Shimoda K, Jerling M, Bottiger Y, Yasuda S, Morita S, Bertilsson L: Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Psychopharmacol 1999;19:393-400.
106. Ruiz S, Chu P, Sramek J, Rotavu E, Hererra J: Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt. Sinai J Med 1996;63(5-6):306-309.
107. Ruiz P, Varner RV, Small DR, Johnson BA: Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatric Q 1999;79(2):163-172.
108. Wong JZ, Beiser M, Zipursky RB, Bean G: An investigation on ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998;81:333-339.
109. Jann MW, Chang WH, Davis CM, Chen TY, Deng HC, Lung FW, et al: Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res 1989;30:45-52.
110. Lin KM, Poland RE, Lau JK, Rubin RT: Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8(3):195-201.
111. Chong SA, Tan CH, Khoo YM, Lee HS, Wong KE, Ngui F, et al: Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 1997;19:219-223.
112. Lane HY, Liu HC, VanDenBerg CM, Su MH, Jann MW, Chang WH: Disposition of olanzapine in Chinese schizophrenic patients. Int J Clin Pharmacol Ther 2000;38(10):482-485.
113. Bergstrom RF, Callaghan JT, Cerimele BJ, Radtke DB, Tatum DE: Pharmacokinetics of olanzapine in Caucasian, Chinese and Japanese subjects. Pharm Res 1996;13(9, Suppl.):S424.
114. Sathirakul K, Teng L, Bergstrom R, Wise SD: Olanzapine: assessment of the pharmacokinetics in Chinese and Caucasian subjects. AAPS PharmSci 2000;2(2): Abstract 1861.
115. Kumana CR, Lauder IJ, Chan M, Lo W, Lin HJ: Differences in diazepam pharmacokinetics in Chinese and White Caucasians: relation to body lipid stores. Eur J Clin Pharmacol 1987;32:211-215.
116. Ghoneim MM, Korttila K, Chiang CK, Jacobs L, Schoenwald RD, Mewalt SP, et al: Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981;29(6):749-756.
117. Zhang YA, Reviriego J, Lou YQ, Sjoqvist F, Bertilsson L: Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with White subjects. Clin Pharmacol Ther 1990;48:496-502.
118. Lin KM, Lau JK, Smith R, Phillips P, Antal E, Poland RE: Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology 1988;96:365-369.
119. Chavez-Teyes L, Lauder IJ, Chan M, Ko W, Lin HJ: Pharmacokinetics of midazolam in Mexicans: evidence for interethnic variability. Clin Drug Invest 1999;17(3):233-239.
120. Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, et al: CYP3A activity in European American and Japanese men using midazolam as an in vitro probe. Clin Pharmacol Ther 2001;69:333-339.
121. Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, et al: Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996;41:69-72.
122. Ajir K, Smith M, Lin KM, Fleishaker JC, Chambers JH, Anderson D, et al: The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology 1997;129:265-270.
123. Gerven JMA, Uchida E, Uchida N, Pieters MSM, Meinders AJ, Schoemaker RC, et al: Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol 1998;38:1129-1136.
124. Edeki TI, Brase DA: Phenytoin disposition and toxicity, role of pharmacogenetic and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab Rev 1995;27(3):449-469.
125. Arnold K, Gerber N: The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther 1970;11:121-134.
126. Watanabe M, Iwahashi K, Kugoh T, Suwaki H: The relationship between phenytoin pharmacokinetic and the CYP2C19 Genotype in Japanese epileptic patients. Clin Neuropharmacol 1998;21(2):122-126.
127. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds CF III: S-mephenytoin 4 hydroxylation in older Americans. Eur J Clin Pharmacol 1991;40:609-611.
128. Bertilsson L, Kalow W: Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in White and Korean population but not in Chinese populations. Clin Pharmacol Ther 1993;53:608-610.
129. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR: Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994;4(1):27-38.
130. Glezko AJ, Peterson FE, Chang T, Dill WA, Smith TC, Buchanan RA: Phenytoin metabolism in subjects with long and short plasma half-lives. Ther Drug Monit 1982;4:281-292.
131. Miller R, Rheeders M, Klein C, Suchet I: Population pharmacokinetics of phenytoin in South African Black patients. S Afr Med J 1987;72;188-190.
132. Inaba T: Phenytoin pharmacogenetic polymorphism of 4-hydroxylation. Pharmacol Ther 1990;46(3):342-347.
133. Chan E, Lee HS, Hue SS: Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol 2001;51:567-576.
134. Johnson JA, Burlew BS: Racial differences in propranolol pharmacokinetics. Clin Pharmacol Ther 1992;51:495-500.
135. Johnson JA: Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997;86:1328-1333.
136. Johnson JA, Burlew BS: Comparison of systemic clearance of propranolol enantiomers in Blacks and Whites. Pharmacotherapy 1992;12:506.
137. Sharoky M, Perkal M, Turner R, Lesko LJ: Steady state relative bioavailability and pharmacokinetics of oral propranolol in Black and White North Americans. Biopharmaceut Drug Dispos 1988;9:447-456.
138. Prisant LM, Mensah GA: Use of beta-adrenergic receptor blockers in Blacks. J Clin Pharmacol 1996;36(10):867-873.
139. Rutledge DR, Wallace A, Steinberg JD, Cardozo L, Lavine SJ: Racial differences in drug response: isoproterenol effects before and after oropranolol. Pharmaceut Res 1991;8:754-757.
140. Sowinski KM, Burlew BS, Johnson JA: Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men. Clin Pharmacol Ther 1995;57:678-683.
141. Haywood LJ: Hypertension: possible differential risk for Blacks in Beta-Blocker Heart Attack Trial (BHAT). Am J Hypertension 1989;2(11, Pt. 1):865-868.
142. Zhou H, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ: Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 1989;320:565-570.
143. Rasool AH, Rahman AR, Ismail R, Hatim S, Abdullah AR, Singh R, et al: Ethnic differences in response to non-selective beta-blockade among racial groups in Malaysia. Int J Clin Pharmacol Ther 2000;38:260-269.
144. Lang CC, Stein CM, Brown RM, Deegan R, Nelson R, He HB, et al: Attenuation of isoproterenol-mediated vasodilatation in Blacks. N Engl J Med 1995;333(3):155-160.
145. Evans DAP, McLeod HL, Pritchard S, Tariq M, Mobarek A: Interethnic variability in human drug responses. Drug Metab Dispos 2001;29:606-610.
146. Evans WE, Hon YY, Bomgaars L, et al: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-2301.
147. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ: Vasodilation in Black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997;62(4):436-443.
148. Williams RL, Thakker KM, John V, Lin ET, Liang-Gee W, Benet LZ: Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. Pharmaceut Res 1991;8:744-749.
149. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB: Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000;68:130-142.
150. Abou-Auda HS, Najjar TA, Al-Fawzan NF, Gilzai NM: Ethnic differences in nifedipine pharmacokinetics and pharmacodynamics: comparison of Middle Eastern Arabs with other populations. Saudi Pharmaceut J 1998;6:217-227.
151. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG: Ethnic differences in nifedipine kinetics: comparisons between Nigerian, Caucasians and South Asians. Br J Clin Pharmacol 1995;40(5):489-493.
152. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF: Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-58.
153. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF: Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991;31:399-403.
154. Joubert PH, Brandt HD: Apparent racial difference in response to angiotensin I infusion. Eur J Clin Pharmacol 1990;39:183-185.
155. Ping PYA, Hu OY-P, Pool PE, Liao W-C: Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Human Hypertension 2000;14:163-170.
156. Ding PYA, Chu K-M, Hu OY-P, Huang G-M, Jeng J-J, Chang A, et al: Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. J Clin Pharmacol 1999;39:155-160.
157. Anderson PJ, Critchley JAJH, Tomlinson B: The pharmacokinetics and pharmacodynamics of cilazapril in Chinese and Caucasian healthy volunteers. J Physiol Pharmacol 1994;128(Suppl. 1):72.
158. Anderson PJ, Critchley JAJH, Tomlinson B, Resplandy G: Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Br J Clin Pharmacol 1995;39:361-368.
159. Yu HCM, Chan TYK, Critchley JAJH, Woo KS: Factors determining the maintenance dose of warfarin in Chinese patients. Q J Med 1996;89:127-135.
160. Blann A, Hewitt J, Siddiqui F, Bareford D: Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-209.
161. Yu CM, Chan TYK, Tsoi WC, Sanderson JE: Heparin therapy in the Chinese: lower doses are required. Q J Med 1997;90:535-543.
162. Marinac JS, Willsie SK, Dew M, Pourakbar M, Herndon B: Pharmacodynamics effects of dopamine stratified by race. Am J Ther 2001;8:27-34.
163. Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M: An enantiomer-enantiomer interaction of S-R propafenone modifies the effect of racemic drug therapy. Circulation 1994;89:2396-2400.
164. Li G, Gong P-L, Qui J, Zeng F-D, Klotz U: Stereoselective steady state disposition and action of propafenone in Chinese subjects. Br J Clin Pharmacol 1998;46:441-445.
165. Goldberg MJ, Spector R, Johnson GF: Racial background and lidocaine pharmacokinetics. J Clin Pharmacol 1982;22:391-394.
166. Boggs WM, McCree D, Goodwin P, Sharoky M: Lack of relationship between race or cigarette smoking and bioavailability or clonidine. J Clin Pharmacol 1988;28:927.
167. Gross AS, Bridge S, Shenfield GM: Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol 1999;47:151-156.
168. Jonsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, et al: Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 2000;55:721-727.
169. Davis TME, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, Barrett PHR: Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol 2000;49:223-230.
170. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM: Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:2329-2334.
171. Chiu KC, Cohen P, Lee NP, Chuang LM: Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 2000;23:1353-1358.
172. Raji A, Seely EW, Arky RA, Simonson DC: Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001;86:5366-5358.
173. Wise SD, Seah ES, Koivisto V: Pharmacodynamics (PD) and pharmacokinetics (PK) of subcutaneous insulin and insulin Lispro in 3 ethnic groups. Diabetologia 1999;42:A238.
174. Goldzieher JW, Tazewell SD, de la Pena A: Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. Contraception 1980;21(1):1-17.
175. Coelingh Bennink HJT: The pharmacokinetics and pharmacodynamics of Implanon ®, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(2):12-20.
176. Goldzieher JW, Brody SA: Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 1990;163(6):2114-2119.
177. Goldzieher JW, Williams MC: Chromatographic patterns of urinary ethynyl estrogen metabolites. Steroids 1980;36:255-282.
178. Goldzieher JW: Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynecol 1989;160(5):1260-1264.
179. Muck W, Unger S, Kawano K, Ahr G: Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998;45:583-590.
180. Ahlstrom H, Alvero J, Alvero R, Espos R, Fajutrao L, Herrera J, et al: Pharmacokinetics of bambuterol during oral administration to asthmatic children. Br J Clin Pharmacol 1999;48:299-308.
181. Mohamed MHN, Lima JJ, Eberle LV, Self TH, Johnson JA: Effects of race and gender on albuterol pharmacokinetics (PK). Clin Pharmacol Ther 1998;63:164.
182. Jeong, CS, Hwang SC, Jones DW, Ryu WS, Sohn K, Sands CD: Theophylline disposition in Korean patients with congestive heart failure. Ann Pharmacother 1994;28:396-401.
183. Lindholm A, Welsh M, Alton C, Kahan B: Demographic factors influencing cyclosporine pharmacokinetics parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992;52(4):359-371.
184. Cooney G, Dunn S, Sommerauer J, Lindsay C, McDiarmid S, Choc M, et al: Improved bioavailability in Black pediatric liver transplant recipients after administration of the microemulsion formulation. Liver Transplant Surg 1999;5:112-118.
185. Min D, Lee M, Ku Y, Flanigan M: Gender-dependent racial difference in disposition of cyclosporine among healthy African American and White volunteers. Clin Pharmacol Ther 2000;68:478-486.
186. Palma-Aguirre J, Gonzalez-Llaven J, Flores-Murrieta F, Castaneda-Hernandez C: Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997;37:630-634.
187. Lemire J, Capparelli E, Benador N, Grimm P, Macdonald D, Reznik V: Neoral pharmacokinetics in Latino and Caucasian pediatric renal transplant recipients. Pediatr Nephrol 2001;16:311-314.
188. Pollack R, Wong R, Chang C: Cyclosporine bioavailability of Neoral and Sandimmune in Black and White de novo renal transplant recipients. Ther Drug Monit 11999;21:661-663.
189. Lee M, Min D, Ku Y, Flannigan M: Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol 2001;41:317-323.
190. Shaw L, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, et al: Mycophenolic acid area under the curve values for African American and Caucasian renal transplant patients as comparable. J Clin Pharmacol 2000;40:624-633.
191. Mancinelli L, Frassetto L, Floren L, Dressler D, Carrier S, Bekersky I, et al: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24-31.
192. Tanigawara Y, Sasaki Y, Otsu T, et al: Population pharmacokietics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 1996;15:479.
193. Tanigawara Y: Pharmacokinetic studies to support clinical trials: from scientific perspective. Yakubutsu Dotai (Xenobiotic Metabolism and Disposition) 1999;14:231-237.
194. Ratain MY, Rosner G, Allen SL, et al: Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 1995;13:741-747.
195. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE: Thiopurine methyltransferase activity in American White subjects and Black subjects. Clin Pharmacol Ther 1994;55:15-20.
196. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-572.
197. Kumagai K, Hiyama K, Ishioka S, et al: Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11:275-278.
198. Zhihong L, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
199. Caraco Y, Lagerstrom PO, Wood AJJ: Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60(2):157-167.
200. Bender W, Brockmeier D: Pharmacokinetic characteristics of roxatidine. J Clin Gastroenterol 1989;11(Suppl. 1):S6-S19.
201. Flores-Murrieta F, Castaneda-Hernandez G, Herrera J, Hong E: Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. Arch Med Res 1994;25:381-385.
202. Jhee S, Burm J, Gill M: Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic and Caucasian patients using population pharmacokinetics methods. Antimicrob Agents Chemother 1994;38:2073-2077.
203. Oparaoji E, Siram S, Elemihe U, Mezghebe H, Cho T, Bashiri M, et al: Aminoglycoside pharmacokinetics in African-Americans with normal renal function. J Clin Pharm Ther 1998;23:191-197.
204. Ali H, Homeida M, El-Zein I: Effect of ethnic origin on ampicillin bioavailability in healthy Sudanese subjects. Br J Clin Pharmacol 1983;16:576-577.
205. Yates R, Adam H, Donnelly R, Houghton H, Young J: Pharmacokinetics and tolerance of a single intramuscular dose of cefotetan in normal Caucasian volunteers. Drugs Exp Clin Res 1983;9:225-228.
206. Walker O, Salako L, Alvan G, Ericsson O, Sjoqvist F: The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol 1987;23:295-301.
207. Price Evans D, Fletcher K, Baty J: The urinary excretion of chloroquine in different ethnic groups. Ann Trop Med Parasitol 1979;73:11-17.
208. Ward S, Mihaly G, Edwards G, Looareesuwan S, Phillips R, Chanthavanich P, et al: Pharmacokinetics of primaquine in man: II. Comparison of acute vs. chronic dosage in Thai subjects. Br J Clin Pharmacol 1985;19:751-755.
209. Viriyayudhakorn S, Wanwimolruk S: Pharmacokinetics of quinine in Asians (Thai) and White Caucasians. Asia Pacific J Pharmacol 1996;11:47-51.
210. Cook I, Cochran J, Edstein M: Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis. Trans Royal Soc Trop Med Hygiene 1986;80:897-901.
211. Flores-Murrieta FJ, Castaneda-Hernandez G, Granados-Soto V, Herrera J: Increased bioavailability of sildenafil in Mexican men. JAMA 2000;283(14):1825-1826.
212. Dohman K, Baraona E, Ishibashi H, Pozzato G, Moretti M, Matsunaga C, et al: Ethnic differences in gastric σ-alcohol dehydrogenase activity and ethanol first-pass metabolism. Alcohol Clin Exp Res 1996;20;1569-1576.
213. Li T, Beard J, Orr W, Kwo P, Ramchandani V, Thomasson H: Variation in ethanol pharmacokinetics and perceived gender and ethnic differences in alcohol elimination. Alcohol Clin Exp Res 2000;24:415-416.
214. Grant D, Tang B, Kalow W: Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
215. Benowitz N, Perez-Stable E, Fong I, Modin G, Herrera B, Jacob P: Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999;291:1196-1203.
216. Caraballo R, Giovino G, Pechacek T, Mowery P, Richter P, Strauss W, et al: Racial and ethnic differences in serum cotinine levels of cigarette smokers. JAMA 1998;280:135-139.
217. Lin S, Ho H, Chien Y: Development of a new nicotine transdermal delivery system: in vitro kinetic studies and clinical pharmacokinetics evaluations in two ethnic groups. J Control Release 1993;26:175-193.
218. Brown RO, Dickerson RN: Drug-nutrient interactions. Am J Manag Care 1999;5(3):345-352.
219. Fleisher D, Li C, Zhou Y, Pao LH, Karim A: Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999;36(3):233-254.
220. Thomas JA: Drug-nutrient interactions. Nutr Rev 1995;53(10):271-282.
221. Tschanz C, Stargel WW, Thomas JA: Interactions between drugs and nutrients. Adv Pharmacol 1996;35:1-26.
222. Jusko WJ: Role of tobacco smoking in pharmacokinetics. J Pharmacokin Biopharm 1978;6:7-39.
223. Lin K-M, Smith MW, Ortiz V: Culture and psychopharmacology. Psychiatr Clin North Am 2001;24:523-538.
224. Perel JM, Yurasits L, Brown C, Schulberg HC: Implications of pharmacologic assessments of nortriptyline compliance. Clin Pharmacol Ther 1998;63:238.
225. Lacombe PS, Vicente JAG, Pages JC, Morselli PL: Causes and problems of nonresponse or poor response to drugs. Drugs 1996;51:552-570.